NDT Advance Access originally published online on February 19, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nephrol Dial Transplant (2004) 19: 1224-1230
Nephrol Dial Transplant Vol. 19 No. 5 © ERA-EDTA 2004; all rights reserved
Original Article
Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients
1Klinikum Hannover Oststadt, Hannover, 2Department of Nephrology, University of Heidelberg, 3KfH Centers for Dialysis, Nürnberg and 4Straubing, 6Amgen, Munich, Germany and 5Amgen, Cambridge, UK
Correspondence and offprint requests to: Professor Reinhard Brunkhorst, Krankenhaus Oststadt, Podbielskistrasse 380, D-30659 Hannover, Germany. Email: sekretariat.brunkhorst.oststadt{at}klinikum-hannover.de
Background. Darbepoetin alfa is a unique molecule that stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Due to its 
3-fold longer half-life and greater biological activity than recombinant human erythropoietin (rHuEpo), darbepoetin alfa maintains effective haemoglobin control at extended dose intervals compared with rHuEpo. This study assessed the efficacy and safety of unit doses of darbepoetin alfa for the treatment of renal anaemia.
Methods. In this multicentre, prospective, open-label study, 1502 dialysis subjects maintained on stable rHuEpo treatment were switched to darbepoetin alfa at extended dose intervals by the same route of administration as previous rHuEpo therapy [intravenous (i.v.), n = 900 or subcutaneous (s.c.), n = 602]. Subjects receiving rHuEpo two (n = 408, 27%) or three times (n = 884, 59%) a week were switched to darbepoetin alfa once a week, and those receiving rHuEpo once a week (n = 210, 14%) were switched to darbepoetin alfa once every 2 weeks. The unit doses of darbepoetin alfa (10–150 µg) were titrated to maintain haemoglobin concentrations of 10–13 g/dl for 24 weeks.
Results. Haemoglobin concentrations were maintained effectively in subjects regardless of whether they received darbepoetin alfa once a week or once every 2 weeks. The overall mean change in haemoglobin from baseline to the evaluation period (weeks 21–24) was +0.10 g/dl [95% confidence interval (CI) 0.04± 0.17]. The mean haemoglobin concentration increased by 0.19 g/dl (95% CI 0.11±0.27) in subjects receiving i.v. darbepoetin alfa, and was unchanged (–0.02 g/dl; 95% CI –0.12 to 0.07) in patients treated with s.c. darbepoetin alfa. Subjects with baseline haemoglobin < 11 g/dl experienced a clinically relevant increase in mean haemoglobin concentration of 0.67 g/dl (95% CI 0.56±0.77) from baseline to the evaluation period. The mean weekly i.v. and s.c. darbepoetin alfa dosage requirements during the evaluation period were 19.9 µg/week (95% CI 19.02±20.87) and 21.6 µg/week (95% CI 20.36± 22.94), respectively. Darbepoetin alfa was well tolerated and the safety profile was consistent with previous trials with darbepoetin alfa in dialysis subjects.
Conclusions. Treating renal anaemia with darbepoetin alfa administered at extended dose intervals is both effective and well tolerated. Moreover, administration of darbepoetin alfa by both the i.v. and s.c. route is associated with stable haemoglobin concentrations.
Keywords: darbepoetin alfa; dialysis; haemoglobin; renal anaemia; route of administration; safety
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Bonafont, A. Bock, D. Carter, R. Brunkhorst, F. Carrera, M. Iskedjian, B. Molemans, B. Dehmel, and S. Robbins A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis NDT Plus, October 1, 2009; 2(5): 347 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Fang and C.-H. Chang SUBCUTANEOUS ADMINISTRATION OF DARBEPOETIN ALFA EFFECTIVELY MAINTAINS HEMOGLOBIN CONCENTRATIONS AT EXTENDED DOSE INTERVALS IN PERITONEAL DIALYSIS PATIENTS Perit. Dial. Int., March 1, 2009; 29(2): 199 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kalantar-Zadeh and G. R. Aronoff Hemoglobin Variability in Anemia of Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2009; 20(3): 479 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Carrera and M. Burnier Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations NDT Plus, January 1, 2009; 2(suppl_1): i9 - i17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tomasello Anemia of Chronic Kidney Disease Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195. [Abstract] [PDF]
|
|
|
|
 |
|
 I. C. Macdougall, D. Padhi, and G. Jang Pharmacology of darbepoetin alfa Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv2 - iv9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Carrera, A. Disney, and M. Molina Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv19 - iv30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Schmitt, B. Nau, C. Brummer, J. Rosenkranz, and F. Schaefer Increased injection pain with darbepoetin-{alpha} compared to epoetin-{beta} in paediatric dialysis patients Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3520 - 3524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aarup, J. Bryndum, H. Dieperink, and P. Joffe Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1312 - 1316. [Abstract] [Full Text] [PDF]
|
|